First-in-human uPAR PET: Imaging of Cancer Aggressiveness

Morten Persson, Dorthe Skovgaard, Malene Brandt-Larsen, +13

Theranostics

Imaging BiomarkersEngineeringOncologic ImagingPet-mriPositron Emission Tomography +14

Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with ⁶⁴Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion

Morten Persson, Jacob Madsen, Søren Østergaard, +5

Journal of Nuclear Medicine

High tumor uptake of 64Cu: Implications for molecular imaging of tumor characteristics with copper-based PET tracers

Jesper Tranekjær Jørgensen, Morten Persson, Jacob Madsen, +1

Nuclear Medicine and Biology

Positron Emission TomographyEngineeringOncologic ImagingMedical ImagingPet-mri +9

Safety, Dosimetry, and Tumor Detection Ability of ⁶⁸Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging

Dorthe Skovgaard, Morten Persson, Malene Brandt-Larsen, +11

Journal of Nuclear Medicine

68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers

Morten Persson, Jacob Madsen, Søren Østergaard, +1

Nuclear Medicine and Biology

Nodaga-conjugated PeptideEngineeringOncologic ImagingPet ImagingTheranostics +8

uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model

Anders Christensen, Karina Juhl, Morten Persson, +7

Oncotarget

Improved PET Imaging of uPAR Expression Using new ⁶⁴Cu-labeled Cross-Bridged Peptide Ligands: Comparative <i>in vitro</i> and <i>in vivo</i> Studies

Morten Persson, Masood Hosseini, Jacob Madsen, +3

Theranostics

First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts

Morten Persson, Hongguang Liu, Jacob Madsen, +1

Nuclear Medicine and Biology

Positron Emission TomographyUrologyImaging BiomarkersVivo StudiesMedical Imaging +10

New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Morten Persson, Palle Rasmussen, Jacob Madsen, +1

Nuclear Medicine and Biology

Drug TargetingOncologyVivo StudiesMedicineRadionuclide Therapy +9

uPAR Targeted Radionuclide Therapy with ¹⁷⁷Lu-DOTA-AE105 Inhibits Dissemination of Metastatic Prostate Cancer

Morten Persson, Karina Juhl, Palle Rasmussen, +3

Molecular Pharmaceutics